News

Kenox Pharmaceuticals Now Clinical Manufacturing Ready for Nasal and Inhaled Therapies

Back

Princeton, NJ – Kenox Pharmaceuticals Inc. (Kenox) is pleased to announce that the company is now fully Clinical Manufacturing Ready, strengthening its capabilities to support the development of nasal and inhaled drug products. This milestone enhances Kenox’s integrated platform for Orally Inhaled and Nasal Drug Products (OINDPs), including expanded GMP analytical testing and in vitro bioequivalence (IVBE) capabilities. With integrated R&D, formulation development, device and aerosol testing, fill–finish, and GMP release services, Kenox provides partners with a streamlined path from early development to clinical supply. The company supports both sterile and non-sterile fill–finish operations across small molecules, peptides, and biologics, enabling faster and more efficient development while maintaining the highest standards of quality and regulatory compliance.

For more information, see our recent news Click here.

If you would like to discuss your project or learn more about our capabilities, please reach out to us at bd@kenoxpharma.us.